

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569

Status	RECRUITING
Phase	Phase 2
Sponsor	Sanofi
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (6)

- Participants are eligible to be included in the study only if all of the following criteria apply:
- Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 6 months prior to Baseline
- Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), with at least 1 body site being Hurley Stage II or III.
- Participant must have a total abscess and inflammatory nodule (AN) count of e5 at the Baseline Visit.
- Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics or demonstrated intolerance to antibiotics or has a contraindication to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.

... and 1 more (see full listing online)

Exclusion (9)

- Participants are excluded from the study if any of the following criteria apply:
- Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS.
- History of recurrent or recent serious infection
- Known history of or suspected current immunosuppression
- History of solid organ transplant or stem cell transplant.

... and 4 more (see full listing online)

Locations (20 total)

Scottsdale Clinical Trials- Site Number : 8400006, Scottsdale, Arizona, United States

Carbon Health - North Hollywood - NoHo West- Site Number : 8400017, North Hollywood, California, United States

Encore Medical Research of Boynton Beach- Site Number : 8400005, Boynton Beach, Florida, United States

... and 17 more locations